New test allows to advance lung cancer treatment

2017-07-05

New test allows to advance lung cancer treatment

Following two-year testing, US FDA has permitted to use Oncomine Dx Target Test in hospitals for lung cancer treatment. This genetic test allows to define a certain type of tumor affected lungs in a record-breaking short term and, consequently, to assign patients a proper therapy. Conventional methods are not always accurate in this case and require lots of time (weeks and even months), while Oncomine Dx Target Test can provide accurate results in four days.

The test is a special analysis of a tiny particle of tumor tissue. At the end of this analysis, a doctor obtains data on changes that this tumor causes in 23 genes. The information of three kinds of them, ROS1, EGFR, and BRAF, is especially valuable, as it allows to determine what pharmaceutical drug is the most efficient in each specific case.

Fisher Scientific has been already applying this solution in US two largest laboratories, specializing in cancer diagnostics.

Innovation news

02.08.21
Development of Medical Applications. Features, Benefits, First Steps

The world is now experiencing an active development of IT sphere and, in particular, innovative...

29.07.21
Safe Healthcare Technologies During the COVID-19 Pandemic

Virtual services are actively developing in all activities. It has become a new trend in...

29.07.21
Teledentistry as an innovative segment in healthcare: Peculiarities and benefits

COVID-19 pandemic has made many adjustments to the modern world. People began to take advantage...